Abstract
High serum ferritin levels have been previously associated with poor outcomes following intracerebral hemorrhage (ICH), suggesting iron's detrimental role in brain injury. This study investigated temporal changes in serum iron, ferritin, transferrin (Tf), and ceruloplasmin (CP) in 100 ICH patients across 21 days compared to 75 healthy controls. Results showed that patients with poor functional outcomes (mRS ≥ 3 at 90 days) exhibited significantly higher serum ferritin and markedly lower serum iron and Tf from admission through Day 7. Furthermore, serum ferritin positively correlated with edema and hematoma volumes, while serum iron and Tf showed negative correlations with initial hematoma volume. These findings suggest that a combined profile of these iron markers serves as a potent predictor of clinical outcome.
Introduction
Intracerebral hemorrhage (ICH) is a severe form of stroke characterized by a ruptured blood vessel in the brain, leading to high rates of mortality and long-term disability. A critical factor in secondary brain injury following the initial bleed is the neurotoxicity of iron, released during the breakdown of red blood cells within the hematoma. While high ferritin levels—a marker of iron storage—are known to correlate with poor outcomes, the broader systemic response of iron metabolism, including transport (transferrin) and enzymatic regulation (ceruloplasmin), has been less clear. This study aimed to determine if a multi-marker "iron signature" could provide superior prognostic value.
Methods
Researchers conducted a prospective study involving 100 consecutive patients with acute spontaneous ICH and 75 healthy age- and sex-matched controls.
- Biomarker Analysis: Serum levels of iron, ferritin, Tf, and CP were measured at Day 1 (admission), 3, 7, 14, and 21.
- Neuroimaging: CT scans on Day 1 and Day 3 quantified hematoma and perihematomal edema volumes.
- Outcome Assessment: Functional recovery was evaluated at 90 days using the Modified Rankin Scale (mRS), where a score of ≥ 3 indicated a poor outcome.
Results and Key Insights
The study identified a distinct divergence in iron metabolism between patients with good and poor outcomes. Of the 100 patients, 59 experienced poor outcomes.
The Systemic Iron Signature
Patients with poor outcomes demonstrated a specific systemic profile: significantly elevated ferritin levels coupled with significantly reduced serum iron and transferrin compared to both the good-outcome group and healthy controls. This divergence was evident as early as Day 1 and persisted through the first week of hospitalization.
Correlation with Brain Injury
- Ferritin and Edema: Serum ferritin levels on admission and Day 3 showed a significant positive correlation with relative edema volume, suggesting that higher iron storage markers reflect greater brain swelling.
- Iron/Tf and Hematoma Size: Conversely, lower serum iron and Tf levels on admission were strongly correlated with larger initial hematoma volumes. This "iron paradox" suggests that during a major bleed, circulating iron is rapidly sequestered or relocated to brain tissue, depleting the systemic supply.
- Specificity: Interestingly, ceruloplasmin (CP) levels did not show significant changes or correlations with outcomes, suggesting that the observed shifts in iron, Tf, and ferritin are specific to iron dysregulation rather than a general inflammatory response.
Discussion and Future Directions
The findings highlight that a combination of high ferritin, low iron, and low transferrin is a more reliable predictor of functional outcome than ferritin alone. This early "iron signature" could help clinicians identify high-risk patients shortly after admission.
However, the study is limited by its sample size and observational nature; it remains unclear if these systemic changes actively contribute to brain injury or are merely markers of its severity. Future research should investigate the role of hepcidin, the master regulator of iron, and explore whether therapeutic interventions like iron chelators could mitigate oxidative stress and improve recovery in ICH patients.
Summary updated